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Abstract 
Review on t(8;14)(q24;q32) / t(2;8)(p12;q24) / 
t(8;22)(q24;q11), with data on clinics, and the genes 
involved. 
Identity 
Note 
The 3 translocations are variants of each other, and 
they share the same clinical significance. 
Top row: t(2;8)(p12;q24) G- banding - Courtesy Diane H.Norback, Eric B. Johnson, Sara Morrison-Delap; R- banding - (middle 
right) Courtesy Jean-Luc Lai; (right) Courtesy Hossein Mossafa; below: Courtesy Roland Berger.  Middle rows: t(8;14)(q24;q32) 
G- banding - (left, middle left, center) Courtesy Diane H. Norback, Eric B. Johnson, Sara Morrison-Delap; R- banding - middle 
right Courtesy Jean-Luc Lai; right: Jean Loup Huret; below: Courtesy Roland Berger. Lower row: t(8;22)(q24;q11) G- banding 
(left and center) - Courtesy Diane H. Norback, Eric B.Johnson, Sara Morrison-Delap UW Cytogenetic Services; R- banding - 
(right) Courtesy Jacques Boyer. 
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Bone marrow sample: the medium-sized cells show a diffuse monotonous pattern of infiltration. The nuclei are round, cytoplasm 
deeply basophilic and usually contain vacuoles. The morphological feature in this bone marrow smear (Giemsa), quite similar to 
tumor cells as seen in tissue imprints, is highly characteristic of Burkitt lymphoma - Text and iconography Courtesy Georges 
Flandrin 2005. 
 
Clinics and pathology 
Disease 
described both in B-cell acute lymphoblastic 
leukemia (ALL) and in non-Hodgkin lymphomas 
(NHL), especially in the Burkitt lymphoma , and 
'double-hit' diffuse large B-cell 
lymphomas  (DLBCL). 
Phenotype/cell stem origin 
The postulated normal counterpart is the germinal 
centre or post-germinal centre B-cell. 
Epidemiology 
Most Burkitt lymphoma cases show the 
t(8;14)(q24;q32) MYC/IGH and less commonly the 
t(8;22)(q24;q11) or t(2;8)(p12;q24). The 
translocation is present in both the endemic African 
Burkitt lymphoma and in the non endemic tumor 
type (Europe, America, and Japan). In case the 
Burkitt lymphoma infiltrated the bone marrow 
(leukemic phase) the MYC-translocation can be 
demonstrated in the bone marrow or blood as well. 
If no immunophenotyping results are available, it is 
good practice to exclude a BCL2 rearrangement 
because a t(8;14) can be observed in other B cell 
neoplasms (such as double hit DLBCL see below). 
Some DLBCL ('double-hit') cases contain the t(8;14) 
translocation. In some clinical studies patients with 
DLBCL and MYC rearrangement will receive more 
aggressive treatment. The disease defines the 
prognosis. Given the correct treatment regime 
Burkitt lymphoma patients do well, while the 
outcome in double-hit DLBCL patient is totally 
different. 
Cytology 
ALL : L3 morphology according to the FAB 
classification, very occasionally L1 or L2 cytology 
reported. 
Cytogenetics 
 
The figure illustrates the translocation of the c-Myc gene 
(probe 944B18, red) to 14q32.3 - Courtesy Mariano Rocchi. 
Cytogenetics morphological 
t(8;14) is described in 75-85% of the cases, t(2;8) in 
5%, and t(8 ;22) in the remaining 10%; high-quality 
metaphases are required to detect t(8;14) and t(8;22). 
Additional anomalies 
Reported in 70% cases in Burkitt lymphoma and 
DLBCL, especially: t(14;18)(q32;q21) in double-hit 
DLBCL lymphoma's, structural rearrangements of 
the long arm of chromosome 1 (30% cases) resulting 
in a partial trisomy 1q, rearrangements of 13q34 
(15% cases). 
Variants 
t(2;8)(p12;q24) and t(8;22)(q24;q11) are variants of  
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the t(8;14)(q24;q32); three-way rearrangements and 
translocations of submicroscopic chromosome 
fragments have also been described 
Genes involved and 
proteins 
Note 
On the molecular point of view, in all these three 
translocations, the oncogene C-MYC is juxtaposed 
either with the immunoglobulin heavy chain locus 
IGH (14q32), the kappa light-chain locus IGK 
(2p12), or the lambda light-chain locus IGL (22q11); 
all these translocations share a breakpoint in 8q24 
(C-MYC locus). The MYC breakpoints are diverse 
and distributed over a 2Mb region. Therefore it has 
to be noted that not all MYC-rearrangements can be 
detected by FISH. 
MYC 
Location 
8q24 
DNA/RNA 
The human C-MYC oncogene is the cellular 
homologue of an avian retrovirus; in vertebrates, it 
belongs to a small gene family with closely related 
members (MYC, N-MYCN, MYCL); C-MYC has 
three exons; two promoters P1 and P2 control the C-
MYC transcription; the choice of the promoter 
depends on the myc protein level. P2 promoter is 
considered as the most active promoter, generating a 
2.25 kb transcript, whereas P1 promoter enrates a 2.4 
kb transcript; the main part of 5' first exon 
corresponds to an untranslated region, MYC1 
translation starting at a CUG codon near its 3'end, 
having 14 additional N-terminal amino-acids 
compared with MYC2 translation site localized 5' 
near the second exon beginning 
Protein 
Myc protein is a transcription factor of the helix-
loop-helix/leucine zipper family that activates 
transcription as obligate heterodimer with a partner 
protein, MAX. 
Immunoglobulin genes:  
IGH, IGK, IGL 
Location 
 in 14q32, 2p12 and 22q11 respectively. 
Result of the chromosomal 
anomaly 
Hybrid gene 
Note 
No hybrid transcript.  
The translocation leads to the MYC gene under 
direct regulation of the enhancer of the IGH (or 
IGK/IGL genes), thereby causing high level 
transcription of the MYC gene. 
Description 
MYC is translocated to der(14) in the t(8;14), 
whereas it remains on der(8) in the variant 
translocations; t(8;14) leads to a head-to-head fusion 
of MYC with the heavy chain immunogloulin locus 
: 8q24 is close to the 5' extremity of C-MYC exon 2, 
leading the all translated gene region to 14q32; the 
8q24 breakpoint region is variable, scattered over a 
190 Kb region, 5' far from MYC or within MYC; the 
14q32 breakpoint region is mainly located in the 
constant region, very close within the switch or 
joining regions; MYC juxtaposed to the 
immunoglobin constant regions and enhancer is 
overexpressed, shutting down the normal remaining 
MYC; in both t(2;8) and t(8;22), the breakpoint is in 
3' of or distal to the MYC gene which always 
remains on der(8); the rearrangement with 
respectively Igk or Igl and C-MYC is head-to-tail. 
Fusion protein 
Note 
The protein MYC resulting from the translation of 
the second and third exons, through DNA-binding 
properties, plays a role in regulating cell growth and 
differentiation 
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Oncogenesis 
Constitutive expression of c-myc induces 
proliferation even in the absence of growth factors. 
To be noted 
Case Report 
Translocation t(8;14)(q24;q32) as a clue for the 
diagnosis of B cell prolymphocytic leukemia 
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